 Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of updated interim clinical data from the ongoing Phase 12 CIRLL Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with chronic lymphocytic leukemia CLL or mantle cell lymphoma MCL. The results were presented at the American Society of Hematology ASH Annual Meeting in Orlando. A copy of the poster presentation is available online at 